Literature DB >> 30159733

Hemoglobin A1c Has Suboptimal Performance to Diagnose and Monitor Diabetes Mellitus in Patients with Cirrhosis.

Naga S Addepally1, Nayana George2, Roberto Martinez-Macias1, Mauricio Garcia-Saenz-de-Sicilia1, W Ray Kim3, Andres Duarte-Rojo4.   

Abstract

BACKGROUND: Glycated hemoglobin A1c (HbA1c) is routinely used to diagnose and monitor type 2 diabetes mellitus (T2DM) in cirrhotic patients. Remarkably, HbA1c may be falsely low in such patients. AIMS: We assessed the diagnostic and monitoring yield of HbA1c in cirrhotic patients with T2DM (DM-Cirr) and without T2DM (NoDM-Cirr).
METHODS: We conducted a composite study allocating 21 NoDM-Cirr into a cross-sectional module and 16 DM-Cirr plus 13 controls with T2DM only (DM-NoCirr) into a prospective cohort. Oral glucose tolerance test (OGTT) was performed in NoDM-Cirr. DM-Cirr and DM-NoCirr were matched by sex, age, BMI, and T2DM treatment and studied with continuous glucose monitoring (CGM). Percent deviations from target, low/high blood glucose indexes (LBGI/HBGI) were calculated from CGM, as well as the average daily risk range (ADRR) as a marker of glucose variability.
RESULTS: Overall, HbA1c and OGTT diagnostic yield agreed in 12 patients (57%, ρ = 0.45, p < 0.03). CGM captured 3463 glucose determinations in DM-Cirr and 4273 in DM-NoCirr (p = 0.42). Regression analysis showed an inferior association between HbA1c and CGM in DM-Cirr (R2 = 0.52), when compared to DM-NoCirr (R2 = 0.94), and fructosamine did not improve association for DM-Cirr (R2 = 0.31). Interestingly, cirrhosis and Child-Turcotte-Pugh class accounted for HbA1c variance (p < 0.05). Patients in DM-Cirr were less frequently within target glucose (70-180 mg/dL), but at higher risk for hyperglycemia (HBGI > 9) when compared to DM-NoCirr, and they also showed higher glucose variability (ADRR 13.9 ± 2.5 vs. 8.9 ± 1.8, respectively, p = 0.03).
CONCLUSION: HbA1c inaccurately represents chronic glycemia in patients with cirrhosis, likely in relation to increased glucose variability.

Entities:  

Keywords:  Continuous glucose monitoring; Fasting glucose; HbA1c; Oral glucose tolerance test; Prediabetes

Mesh:

Substances:

Year:  2018        PMID: 30159733     DOI: 10.1007/s10620-018-5265-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

Review 1.  Review of hemoglobin A(1c) in the management of diabetes.

Authors:  Emily Jane Gallagher; Derek Le Roith; Zachary Bloomgarden
Journal:  J Diabetes       Date:  2009-01-27       Impact factor: 4.006

Review 2.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

3.  Statistical tools to analyze continuous glucose monitor data.

Authors:  William Clarke; Boris Kovatchev
Journal:  Diabetes Technol Ther       Date:  2009-06       Impact factor: 6.118

Review 4.  2. Classification and Diagnosis of Diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2017-01       Impact factor: 19.112

5.  Calculating confidence intervals for regression and correlation.

Authors:  D G Altman; M J Gardner
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-30

6.  Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes.

Authors:  Giovanni Sartore; Nino Cristiano Chilelli; Silvia Burlina; Annunziata Lapolla
Journal:  Acta Diabetol       Date:  2013-02-16       Impact factor: 4.280

7.  Determination of glycated hemoglobin in patients with advanced liver disease.

Authors:  Theresa Lahousen; Karin Hegenbarth; Rottraut Ille; Rainer-W Lipp; Robert Krause; Randie-R Little; Wolfgang-J Schnedl
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

8.  Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease.

Authors:  Motoi Hashiba; Masafumi Ono; Hideyuki Hyogo; Yukio Ikeda; Kosei Masuda; Reiko Yoshioka; Yoichi Ishikawa; Yuri Nagata; Kensuke Munekage; Tsunehiro Ochi; Akira Hirose; Yasuko Nozaki-Fujimura; Shuhei Noguchi; Nobuto Okamoto; Kazuaki Chayama; Narufumi Suganuma; Toshiji Saibara
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

9.  Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS.

Authors:  Tsunehiro Ochi; Takumi Kawaguchi; Takashi Nakahara; Masafumi Ono; Shuhei Noguchi; Yuichi Koshiyama; Kensuke Munekage; Eisuke Murakami; Akira Hiramatsu; Mitsunari Ogasawara; Akira Hirose; Hiroshi Mizuta; Kosei Masuda; Nobuto Okamoto; Narufumi Suganuma; Kazuaki Chayama; Masahiro Yamaguchi; Takuji Torimura; Toshiji Saibara
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

10.  Relationship between glycated haemoglobin levels and mean glucose levels over time.

Authors:  D M Nathan; H Turgeon; S Regan
Journal:  Diabetologia       Date:  2007-09-13       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.